Pulsed field ablation catheters Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines pulsed field ablation, a method that treats atrial fibrillation by delivering short bursts of electric pulses through a catheter instead of heat or cold, and the catheters and systems built around it. It tests how far pulsed field ablation can displace thermal ablation and how the market changes as Abbott and Kardium join three established makers by 2034.

The shift has been fast. A Citi Research survey of 72 physicians, reported by MedTech Dive in December 2024, expected pulsed field ablation to account for 49 percent of atrial fibrillation ablation procedures in 2025, up from 39 percent in 2024, and Boston Scientific reported on 24 July 2025 that its United States Farapulse sales grew 117 percent in the second quarter. The conclusion is that adoption is already well past the early stage, and the question for the rest of the decade is how far it goes and who holds the share.

Competition has widened. Medtronic reported in November 2025 that its pulsed field ablation sales grew more than 300 percent year over year in its fiscal second quarter, Kardium received FDA approval for its Globe system in September 2025, and Abbott announced FDA approval of Volt on 22 December 2025 on the basis of the VOLT-AF study of 392 patients at 40 centres. The conclusion is that no single maker can rely on being first, and design features such as mapping integration and conscious sedation now decide share.

Growth is moderating even as the method spreads. Boston Scientific reported fourth quarter 2025 sales of USD 5.29 billion, up 12.7 percent, guided to organic growth of 10 to 11 percent for 2026 against 15.8 percent in 2025, and reported four year data on 11 February 2026 showing better long-term success than thermal ablation in paroxysmal atrial fibrillation. The conclusion is that the market has moved from share gain to wider indications and long-term evidence.

The brief treats pulsed field ablation as a high-impact signal with an eight year horizon to 2034. It identifies which systems and companies move first and what each means for device makers, hospitals and electrophysiologists. It is a focused 114-page decision brief that presents an indicative trajectory rather than a segmented market model.

Cardiac ablation treats atrial fibrillation by destroying small areas of heart tissue that trigger the abnormal rhythm, most often around the pulmonary veins. Radiofrequency ablation uses heat and cryoablation uses cold. Pulsed field ablation uses short high-voltage pulses that affect heart muscle cells more than nearby tissue, which gives a faster procedure and a lower risk of damage to the oesophagus and nerves.

Evidence is building on both sides. Farapulse showed better efficacy than a cryoablation catheter in paroxysmal atrial fibrillation in the SINGLE SHOT CHAMPION trial reported at EHRA in 2025, while the BEAT-PAROX-AF trial found pulsed field ablation was not superior to radiofrequency ablation for drug-resistant paroxysmal atrial fibrillation and the MANIFEST-17k registry of real-world use reported a favourable safety profile. The conclusion is that pulsed field ablation matches or beats thermal methods on efficacy and safety, and the case rests on speed and safety more than on a large efficacy gap.

Design differences are now the basis of competition. Abbott Volt is a balloon-in-basket catheter that maps, paces and ablates from one device, works with the EnSite X mapping system and allows conscious sedation instead of general anaesthesia, while Boston Scientific has added the Farapoint catheter for right atrial flutter, which received a CE mark on 1 December 2025. The conclusion is that makers are building full portfolios and workflow advantages, because the core energy is no longer unique.

Four pulsed field systems launched in the United States within a year, namely PulseSelect, Affera Sphere-9, Farapulse and Varipulse, and Abbott and Kardium followed in late 2025. The conclusion is that the first wave of share gain is complete, and the next wave depends on persistent atrial fibrillation labels, mapping-integrated systems and procedure speed.

The limits are competition and price pressure, training and lab capacity, evidence for persistent atrial fibrillation and long-term durability data. Boston Scientific noted slowing United States Farapulse sales amid competition from Medtronic Affera, and the brief tests each limit against the cost trajectory to 2034.

The pulsed field ablation market, covering catheters, generators and associated mapping-integrated systems used for cardiac ablation of atrial fibrillation and other arrhythmias, and excluding radiofrequency and cryoablation systems, cardiac mapping systems sold separately, implantable rhythm devices, and drugs for rhythm control, is valued at USD 5.0–7.0 billion in 2026 and is projected to reach USD 12.38–17.33 billion by 2034, at a CAGR of 12%.

The 2026 base rests on pulsed field catheters, generators and associated systems sold for atrial fibrillation ablation, mainly in the United States, Europe and Japan. Growth then follows procedure volumes, the expansion to persistent atrial fibrillation and new arrhythmias, and the spread into China and other markets.

The forecast is sensitive to price pressure from new entrants, lab capacity and long-term outcome data.

Base case.

The base case assumes pulsed field ablation becomes the default method by about 2027 and growth then follows procedure volumes and new indications, giving a 2034 value near the middle of the range.

Accelerated case.

An accelerated case assumes strong long-term data and rapid growth of ablation in persistent atrial fibrillation and earlier treatment, bringing the inflection to 2026 and lifting the 2034 value to the top of the range.

Delayed case.

A delayed case assumes price pressure and slower lab capacity growth, moving the inflection to 2029 and holding growth at the bottom of the range.

Growth drivers

• Atrial fibrillation prevalence.
• Shorter procedure and lab time.
• Safety against thermal ablation.
• Persistent atrial fibrillation indications.

Enablers

• Mapping system integration.
• Conscious sedation workflows.
• Reimbursement and registry evidence.
• Dual-energy platforms.

Restraints and barriers

• Competition and price pressure.
• Training and lab capacity.
• Evidence against radiofrequency in some patients.
• Skills.

The direction of pulsed field ablation is set by regulatory approvals, procedure time and safety, the atrial fibrillation population, integration with mapping and hospital capacity.

The key participants in pulsed field ablation include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Johnson & Johnson, Kardium Inc., Biotronik SE & Co. KG, Field Medical, Inc., Pulse Biosciences, Inc., CardioFocus, Inc., Stereotaxis, Inc., MicroPort Scientific Corporation, Lepu Medical Technology (Beijing) Co., Ltd., Adagio Medical Holdings, Inc., AtriCure, Inc., Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Arga Medtech SA, Japan Lifeline Co., Ltd., Volta Medical SAS, Integer Holdings Corporation, Terumo Corporation, iRhythm Technologies, Inc., AliveCor, Inc., Apple Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, HCA Healthcare, Inc., Tenet Healthcare Corporation, Apollo Hospitals Enterprise Limited, Mayo Clinic, Cleveland Clinic, the Heart Rhythm Society, the European Heart Rhythm Association, the American Heart Association, the National Institute for Health and Care Excellence and the Centers for Medicare & Medicaid Services.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as pulsed field ablation becomes the default method.

Boston Scientific, Medtronic, Abbott and Johnson & Johnson lead among established electrophysiology makers, Kardium, Field Medical and Pulse Biosciences among new entrants, and Siemens Healthineers, GE HealthCare and Stereotaxis among imaging and robotics companies. Competitive intensity is high and rising as Abbott and Kardium add to a field of three large makers.

Where value migrates.

In 2026 value sits with the makers that hold early share and the largest installed base of mapping systems, because hospitals adopt catheters that fit the lab they already run. By 2028 it moves toward systems with mapping integration, conscious sedation and persistent atrial fibrillation labels as price competition grows. By 2034 it settles with a mature market that tracks procedure volumes and new arrhythmia indications. Margins hold for makers with full portfolios and long-term data, and narrow for makers of single catheters without mapping partners.

The signals converge on a market where adoption is well advanced and competition is widening. FDA approvals from four large makers, sales growth above 100 percent at the first two and four year data support growth, while price pressure, lab capacity and evidence in persistent atrial fibrillation hold back margins.

Structural limits show where progress could slow: the pace of new entrants, the training of electrophysiologists, the capacity of labs and the long-term durability of lesions. The brief therefore tracks four indicators: share of atrial fibrillation ablation done with pulsed field, catheter price per procedure, new approvals and long-term outcome data.

Default adoption first, then mapping-integrated systems and persistent atrial fibrillation labels, then new arrhythmia indications is the expected order of change.